Abstract: The present invention provides an oral preventive or therapeutic agent for skin damage, containing diacylglyceryl ether as an active ingredient represented by the formula (I): wherein R1 denotes C12-24 aliphatic hydrocarbon group having a degree of unsaturation of between 0 and 2; R2 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6; and R3 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6.

Abstract: The present invention relates to PPAR?-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPAR?-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof, as well as uses of the PPAR?-activating pharmaceutical compositions for treating circulatory diseases, arteriosclerosis, lipid metabolism disorder, diabetes and inflammatory diseases.

Abstract: The present invention provides an oral preventive or therapeutic agent for skin damage, containing diacylglyceryl ether as an active ingredient represented by the formula (I): wherein R1 denotes C12-24 aliphatic hydrocarbon group having a degree of unsaturation of between 0 and 2; R2 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6; and R3 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6.

Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: wherein A represents an optionally substituted CH3CnH(2n-2m)— (wherein n denotes an integer of 4 to 22, and m represents an unsaturation number which is an integer of 0 to 7), l represents an integer of 0 to 10, s represents 0 or 1, provided that when s is 0, p+q=4 or 5, but when s is 1, p+q=3 or 4, and in each case, either p or q is an integer of 1 or more, R represents an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and RA represents hydrogen or an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and their use in suppression of platelet aggregation, in suppression of inflammation, and in prevention and treatment of circulatory diseases.

Abstract: The present invention relates to PPAR&ggr;-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPAR&ggr;-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof, as well as uses of the PPAR&ggr;-activating pharmaceutical compositions for treating circulatory diseases, arteriosclerosis, lipid metabolism disorder, diabetes and inflammatory diseases.

Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: 1